Idera Pharmaceuticals, Inc. (IDRA) Reaches $2.49 After 3.00% Up Move; American National Bancshares (AMNB)’s Sentiment Is 1.14

January 14, 2018 - By Adrian Mccoy

American National Bankshares Inc. operates as the bank holding firm for American National Bank and Trust Company that provides financial services and products. The company has market cap of $345.89 million. The firm operates through two divisions, Community Banking, and Trust and Investment Services. It has a 20.02 P/E ratio. It accepts deposit products, including checking, money market, savings, and consumer and commercial time deposits, as well as certificates of deposit.

The stock of Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) is a huge mover today! The stock increased 4.18% or $0.1 during the last trading session, reaching $2.49. About 1.83 million shares traded. Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) has risen 21.13% since January 14, 2017 and is uptrending. It has outperformed by 4.43% the S&P500.The move comes after 7 months positive chart setup for the $485.23 million company. It was reported on Jan, 14 by We have $2.56 PT which if reached, will make NASDAQ:IDRA worth $14.56M more.

Since October 26, 2017, it had 1 insider buy, and 1 sale for $7.48 million activity. 8.00M shares were bought by BAKER BROS. ADVISORS LP, worth $12.00 million on Thursday, October 26. The insider Pillar Invest Corp sold 2.30 million shares worth $4.52M.

Analysts await Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) to report earnings on March, 21. They expect $-0.08 EPS, down 900.00% or $0.09 from last year’s $0.01 per share. After $-0.10 actual EPS reported by Idera Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts -20.00% EPS growth.

Among 4 analysts covering Idera Pharma (NASDAQ:IDRA), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Idera Pharma had 7 analyst reports since January 6, 2016 according to SRatingsIntel. The company was initiated on Wednesday, January 6 by Wedbush. H.C. Wainwright maintained it with “Buy” rating and $4.0 target in Thursday, November 16 report. The firm has “Buy” rating given on Thursday, November 9 by Piper Jaffray. The stock of Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) earned “Buy” rating by Piper Jaffray on Monday, September 11. The stock of Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) earned “Outperform” rating by Wedbush on Wednesday, February 1.

Idera Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of oligonucleotide therapeutics for oncology and rare diseases in the United States. The company has market cap of $485.23 million. It uses two drug discovery technology platforms to design and develop drug candidates, including toll-like receptor targeting technology and third-generation antisense technology. It currently has negative earnings. The companyÂ’s drug candidates include IMO-2125, an agonist that is in Phase I/II clinical trials in combination with ipilimumab and pembrolizumab for the treatment of anti-PD-1 refractory metastatic melanoma and refractory solid tumors; IMO-8400, an antagonist, which is in Phase II clinical trial for the treatment of dermatomyositis.

Investors sentiment decreased to 1.36 in 2017 Q3. Its down 0.10, from 1.46 in 2017Q2. It is negative, as 5 investors sold Idera Pharmaceuticals, Inc. shares while 20 reduced holdings. 11 funds opened positions while 23 raised stakes. 46.97 million shares or 1.60% more from 46.23 million shares in 2017Q2 were reported. Financial Bank Of New York Mellon Corporation reported 343,188 shares stake. Manufacturers Life The holds 90,620 shares or 0% of its portfolio. Parametric Associate Lc reported 11,932 shares. Gru One Trading Lp holds 0% or 56,712 shares in its portfolio. State Street Corp invested 0% in Idera Pharmaceuticals, Inc. (NASDAQ:IDRA). Amalgamated Retail Bank reported 0% in Idera Pharmaceuticals, Inc. (NASDAQ:IDRA). Moreover, Morgan Stanley has 0% invested in Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) for 155,772 shares. State Of Wisconsin Investment Board stated it has 0% of its portfolio in Idera Pharmaceuticals, Inc. (NASDAQ:IDRA). Principal Financial Grp Inc invested in 16,914 shares or 0% of the stock. Northern Tru Corp owns 1.25M shares. Moreover, Palo Alto Limited Liability Corp has 0.06% invested in Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) for 616,355 shares. Connor Clark & Lunn Inv Mngmt Ltd holds 122,025 shares. Ameritas Investment has 7,586 shares. 177,570 were accumulated by Hollencrest Limited Com. Alps Advisors has invested 0% in Idera Pharmaceuticals, Inc. (NASDAQ:IDRA).

Smith Salley & Associates holds 1.39% of its portfolio in American National Bankshares Inc. for 175,788 shares. Corbyn Investment Management Inc Md owns 50,862 shares or 0.67% of their US portfolio. Moreover, Dixon Hubard Feinour & Brown Inc Va has 0.38% invested in the company for 31,740 shares. The Tennessee-based Woodmont Investment Counsel Llc has invested 0.12% in the stock. Naples Global Advisors Llc, a Florida-based fund reported 7,105 shares.

Echostar Corporation-Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.


Free Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: